**Summary**
Fusion Antibodies plc, a Belfast-based contract research organization (CRO) specializing in pre-clinical antibody discovery and engineering, announced a significant contract win on October 8, 2025. The company has been selected by the Antibody Centre of Excellence of a European-based global pharmaceutical company to undertake a multi-target Integrated Therapeutic Antibody Services project. This project involves humanizing a family of VHH antibody fragments, as well as expressing, purifying, and supplying research materials. The contract is expected to generate revenues of at least £175,000 and will be completed within the current financial year.
This win highlights Fusions ability to secure contracts with major pharmaceutical companies, aligning with its strategy to reduce reliance on smaller, more volatile clients and leverage its proprietary technologies like OptiMAL®. The project reinforces Fusions position as a provider of world-class antibody engineering services and its commitment to delivering innovative solutions for long-term partnerships. CEO Adrian Kinkaid expressed satisfaction with the selection, emphasizing the clients recognition of Fusions expertise and capabilities.
Fusion Antibodies, established in 2001 as a spin-out from Queens University Belfast, has a strong track record of completing over 285 humanization projects and working with top global pharmaceutical companies. The company aims to accelerate drug development for its clients through advanced technologies and scientific expertise.